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Abstract Estrogen receptor (ER)-negative cancers have a
poor prognosis, and few targeted therapies are available for
their treatment. Our previous analyses have identified
potential kinase targets critical for the growth of ER-neg-
ative, progesterone receptor (PR)-negative and HER2-
negative, or ‘‘triple-negative’’ breast cancer (TNBC).
Because phosphatases regulate the function of kinase sig-
naling pathways, in this study, we investigated whether
phosphatases are also differentially expressed in ER-neg-
ative compared to those in ER-positive breast cancers. We
compared RNA expression in 98 human breast cancers (56
ER-positive and 42 ER-negative) to identify phosphatases
differentially expressed in ER-negative compared to those
in ER-positive breast cancers. We then examined the
effects of one selected phosphatase, dual specificity phos-
phatase 4 (DUSP4), on proliferation, cell growth, migration
and invasion, and on signaling pathways using protein
microarray analyses of 172 proteins, including
phosphoproteins. We identified 48 phosphatase genes are
significantly differentially expressed in ER-negative com-
pared to those in ER-positive breast tumors. We discovered
that 31 phosphatases were more highly expressed, while 11
were underexpressed specifically in ER-negative breast
cancers. The DUSP4 gene is underexpressed in ER-nega-
tive breast cancer and is deleted in approximately 50 % of
breast cancers. Induced DUSP4 expression suppresses both
in vitro and in vivo growths of breast cancer cells. Our
studies show that induced DUSP4 expression blocks the
cell cycle at the G1/S checkpoint; inhibits ERK1/2, p38,
JNK1, RB, and NFkB p65 phosphorylation; and inhibits
invasiveness of TNBC cells. These results suggest that that
DUSP4 is a critical regulator of the growth and invasion of
triple-negative breast cancer cells.
Keywords TNBC  Phosphatase  Mouse xenograft 
MAPK pathways
Introduction
Breast cancer is the most frequently diagnosed cancer in
women and the second highest cause of cancer-related
death in United States women in 2016 [1]. Selective
estrogen receptor modulators (SERMs) and aromatase
inhibitors are currently used to treat ER-positive breast
cancers [2–6], while anti-HER2 drugs are used to treat ER-
negative HER2-positive breast cancers [7–9]. However,
there are few treatment options available for breast cancers
that do not express ER, progesterone receptor (PR), or the
HER2 protein, otherwise known as ‘‘triple-negative’’ breast
cancers (TNBCs). As no targeted therapy is available for
most TNBC tumors, cytotoxic chemotherapy is the current
treatment strategy.
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We previously conducted cDNA microarray studies to
identify potential therapeutic targets of ER-negative breast
cancers [10]. These studies identified several kinases crit-
ical for the growth of TNBC. In this study, we sought to
identify phosphatases differentially expressed in ER-neg-
ative tumors that also regulate breast cancer growth. We
identified 11 underexpressed and 31 overexpressed phos-
phatases in ER-negative compared to those in ER-positive
breast cancers. We initially focused on those 11 phos-
phatases underexpressed exhibiting decreased expression
in ER-negative tumors and found that of these 11 under-
expressed phosphatases, DUSP4 is the most frequently
deleted phosphatase in ER-negative breast cancer.
DUSP4 specifically regulates extracellular regulated
kinase (ERK), and the phosphatase activity of DUSP4 is
enhanced upon interaction with ERK and p38 [11–13].
DUSP4 expression has been shown to play an important
role in senescence [14] and emerging evidence suggests
DUSP4 is involved in the growth and progression of cancer
[15, 16]. Our results demonstrate that DUSP4 is frequently
deleted in breast cancer and underexpressed in TNBCs, and
that DUSP4 overexpression halts TNBC tumor growth and
invasion. Our results also demonstrate that all three MAPK
proteins (ERK1/2, p38, and JNK1) are negatively regulated
by DUSP4. Moreover, re-expression of DUSP4 also inhi-
bits other growth inducing pathways, including NFjB and
Rb. Overall, this study demonstrates that DUSP4 is fre-
quently deleted in breast cancers and is a critical regulator
of growth and invasion of TNBCs, suggesting DUSP4 is an
important tumor suppressor gene in these aggressive breast
cancers.
Materials and methods
Breast tumor and microarray datasets
All tumors were collected by Dr. Jenny Chang and
approved by the institutional review board of Baylor Col-
lege of Medicine. This tumor set, including tumor stage,
size, and patient race and menopausal status, has been
previously described [10]. In this study, four samples were
removed from the analysis. These four samples had an
unconfirmed ER status or appeared as outliers on the
principal component analysis (PCA) plot and thus removed
from the dataset. Therefore, 98 samples, 56 ER-positive
and 42 ER-negative invasive breast cancers, were used for
this analysis. Gene expression was estimated using the
Robust Multi-array Average (RMA) procedure. We limited
our data and clustering analysis to 262 genes (454 probe-
sets on Affymetrix U133A chip), which encode known
phosphatases and proteins with phosphatase in their name.
We used the most variable probeset for each of the 262
genes. Statistical analysis was done using Partek software
(http://partek.com). The following criteria were used to
find genes differentially expressed between ER-negative
and ER-positive tumors: Benjamini–Hochberg false dis-
covery rate (FDR) p value B 0.1, fold change C1.2
or B0.8.
Cell lines and cell culture
The MCF-7 (HTB-22), MDA-MB-231 (HTB-26), and
MDA-MB-468 (HTB-132) cell lines (American Type
Culture Collection (ATCC), Manassas, VA, USA) were
cultured in DMEM (Cellgro by Mediatech, Inc., Manassas,
VA, USA) supplemented with 10 % fetal bovine serum,
100 U/ml penicillin, and 100 mg/ml streptomycin. These
were grown and maintained as described in Supplementary
Methods. STR profiles were compared to (1) known ATCC
fingerprints (ATCC.org); (2) the Cell Line Integrated
Molecular Authentication database (CLIMA) version
0.1.200808 (http://bioinformatics.istge.it/clima/) [17]; and
(3) the MD Anderson fingerprint database.
Reagents and antibodies
The DUSP4 antibody was purchased from BD Transduc-
tion Laboratories (Lexington, KY, USA). Phospho-ERK1/2
(#4370) and total ERK1/2 (#4372) were purchased from
Cell Signaling Technology, Inc. (Danvers, MA, USA).
Antiactin antibody was purchased from Sigma-Aldrich
Corp. (St. Louis, MO, USA). Antimouse (#NA931 V) and
antirabbit (NA934 V) secondary antibodies were obtained
from GE Healthcare Bio-sciences Corp. (Piscataway, NJ,
USA).
Viral vectors and modification of cell lines
TheDUSP4ORF clone was obtained fromOpen Biosystems
(Huntsville, AL, USA) and cloned into tetracycline (Tet)-
inducible vector (pTIPZ) through a gateway LR clonase
reaction. Final constructs were verified through restriction
digestion and sequencing. Lentiviral vectors were prepared
as described previously [18]. Stable cell lines expressing
inducible cDNAs were generated by lentiviral infection
using a pTIPZ lentiviral expression system in the presence of
4 lg/ml polybrene, followed by puromycin selection at 48 h
post infection. All pTIPZ stable cell lines were maintained in
media with Tet-safe serum (Clontech Laboratories Inc.,
Mountain View, CA, USA).
Quantitative RT-PCR (qRT-PCR) assessments
Quantitative PCR assays of reverse-transcribed transcripts
(4 replicates per transcript) were carried out using an ABI
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PRISM 7900 Sequence Detection System (Life Technolo-
gies (formerly Applied Biosystems Inc., Foster City, CA,
USA), as previously described [10].
Cell growth assays
Cellular proliferation and anchorage-independent growth
were measured as described previously [19].
Cell cycle assays
To measure cell cycle distribution, Tet-inducible cells were
treated for 4 days with or without doxycycline (2 lg/ml) to
induce DUSP4 gene expression. Cells were then harvested and
fixed overnight in 70 % ethanol at -20 C. Cells were then
stained with propidium iodide (PI) (1 lg/ml) in 0.1 % Triton
X-100 and RNase in PBS and analyzed using a FACSCalibur
Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Western blot analysis
Western blot analyses were performed as described previ-
ously [19]. Antibodies used include anti-DUSP4 antibody
(BD Biosciences, San Jose, CA, 1:1000), anti-phospho-
ERK1/2 antibody (1:1000), and anti-ERK1/2 (1:1000)
(both from Cell Signaling Technology Inc., Danvers, MA,
USA). Anti-Vinculin antibody (Sigma-Aldrich Corp., St.
Louis, MO, USA) was used at a 1:2000 dilution.
Boyden chamber invasion assay
Matrigel-coated transwell cell culture chambers (BD
Transduction Laboratory, Lexington, KY, USA) and inserts
of 8 lm pore size (Corning Inc. Life Sciences, Lowell,
MA, USA) were used to measure invasion of TIPZ-DUSP4
in MDA-MB-231 and SUM 159 cells. 3 9 105 cells/well
were placed in the upper chamber of the transwell inserts in
serum-free media. Media containing 10 % FBS was placed
in the lower chambers. All samples were incubated for 20 h
at 37 C in a humidified atmosphere with 5 % CO2. Non-
invasive cells in the upper chambers were removed by
cotton swab. Invasive cells were then fixed and stained
with HEMA3 (Fisher Scientific Company, LLC, Kalama-
zoo, MI, USA). Invasive cells on the lower surface of the
filters which penetrated through the Matrigel were then
mounted on glass slides, counted, and photographed using
a light microscope at 940 magnification. Migration assays
were performed using transwell inserts without Matrigel.
Percent invasion was calculated based on number of cells
invaded divided by number of cells migrated, and the
results were multiplied by 100. All assays were performed
in triplicate and the results shown as average ± standard
deviation.
Reverse phase protein array (RPPA)
RPPA assays were performed in the MD Anderson Core
facility. Experimental details are provided in Supplemen-
tary Materials.
Mouse experiments
Experiments using nude mice (The Jackson Laboratory,
Bar Harbor, ME, USA) were performed in accordance with
M.D. Anderson Institutional Animal Care and Use Com-
mittee (IACUC)-approved protocols. Experimental details
of our mouse experiments are provided in Supplementary
Materials.
Results
Identification of phosphatases differentially
expressed in ER-negative breast cancer
To identify phosphatases differentially expressed in ER-
negative breast cancers, we compared RNA levels in ER-
positive and ER-negative human breast cancer samples
using a strategy analogous to our previous exploration of
kinase expression [10]. Tumor samples from 98 invasive
breast cancer patients (56 ER-positive, 42 ER-negative)
were previously classified as ER positive or ER negative
using IHC staining for ERa [10]. RNA expression in ER-
positive and ER-negative breast tumors was then analyzed
by Affymetrix gene expression profiling to identify mole-
cules differentially expressed in ER-negative breast cancer
compared to those in ER-positive breast cancers. We
identified 31 overexpressed (fold C 1.2, FDR-adjusted
p B 0.1) and 11 underexpressed phosphatases
(fold B 0.80, adjusted p B 0.1) in ER-negative tumors
compared to those in ER-positive tumors (Table 1;
Fig. 1a). Figure 1b shows the hierarchical clustering seen
when only ER-negative tumors are clustered using the
differentially expressed genes identified in Fig. 1a.
Through these analyses, we identified several phosphatases
critical to cell signaling and metabolic pathways in both the
over- and underexpressed phosphatase groups, including
overexpressed phosphatases that regulate kinases and cell
cycle progression (CDC25A, CDC25B, and CDKN3), and
underexpressed phosphatases that regulate the MAPK and
PI3 K pathways (INPP4B, DUSP4, and DUSP11).
Focusing on phosphatases underexpressed in ER-nega-
tive breast cancer, we next investigated whether these
differentially expressed genes were homogeneously
expressed in ER-negative tumors. As shown in Fig. 1b,
these genes are differentially expressed in ER-negative
tumors. The entire ER-negative group is divided into three
Breast Cancer Res Treat (2016) 158:441–454 443
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major subgroups that express different sets of phos-
phatases: TNBC, mixed TNBC?Her2, and predominantly
Her2-positive tumors. We identified six sets of
phosphatases differentially expressed in ER-negative
tumors, including one set of underexpressed and one set of
overexpressed phosphatases for each of the ER-negative
Table 1 Differential expression of overexpressed phosphatases in ER-negative versus ER-positive breast cancer
Gene name Symbol Fold Adjusted
p valuea
Overexpressed phosphatases (C 1.2-fold, p\ 0.1)
Inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 1.87 0.0006
Lipin 1 LPIN1 1.85 0.0000
Protein tyrosine phosphatase-like (proline instead of catalytic arginine), member A PTPLA 1.84 0.0002
Discs, large (Drosophila) homolog-associated protein 5 DLGAP5 1.84 0.0004
Pyruvate dehydrogenase phosphatase catalytic subunit 1 PDP1 1.62 0.0009
Acid phosphatase 1, soluble ACP1 1.56 0.0002
Protein tyrosine phosphatase, receptor-type, Z polypeptide 1 PTPRZ1 1.51 0.0073
Protein tyrosine phosphatase, receptor type, K PTPRK 1.48 0.0239
Protein tyrosine phosphatase, receptor type, C PTPRC 1.46 0.0956
Chromosome 12 open reading frame 5 C12orf5 1.43 0.0038
Protein phosphatase 3, regulatory subunit B, alpha PPP3R1 1.36 0.0000
Pyrophosphatase (inorganic) 1 PPA1 1.36 0.0105
Protein phosphatase 1, catalytic subunit, beta isozyme PPP1CB 1.34 0.0003
Cyclin-dependent kinase inhibitor 3 CDKN3 1.32 0.0508
Protein tyrosine phosphatase-like (proline instead of catalytic arginine), member B PTPLB 1.28 0.0652
Cell division cycle 25B CDC25B 1.27 0.0723
Protein tyrosine phosphatase, nonreceptor type 2 PTPN2 1.26 0.0067
Cell division cycle 14B CDC14B 1.25 0.0531
Signal-regulatory protein alpha SIRPA 1.25 0.0195
Protein phosphatase 2, regulatory subunit B’’, alpha PPP2R3A 1.24 0.0227
Protein tyrosine phosphatase, receptor type, F PTPRF 1.24 0.0723
Myotubularin-related protein 2 MTMR2 1.23 0.0337
Nudix (nucleoside diphosphate linked moiety X)-type motif 15 NUDT15 1.23 0.0358
Cell division cycle 25A CDC25A 1.23 0.0227
Cytochrome c, somatic CYCS 1.22 0.0837
Dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) DUSP11 1.21 0.0358
Nudix (nucleoside diphosphate linked moiety X)-type motif 1 NUDT1 1.21 0.0780
Inositol monophosphatase domain containing 1 IMPAD1 1.20 0.0027
Protein tyrosine phosphatase, nonreceptor type 4 (megakaryocyte) PTPN4 1.20 0.0227
Protein tyrosine phosphatase, nonreceptor type 22 (lymphoid) PTPN22 1.20 0.0024
Underexpressed phosphatases (B0.80-fold, p\ 0.1)
Protein phosphatase 1, regulatory subunit 3C PPP1R3C 0.46 0.0001
Dual specificity phosphatase 4 DUSP4 0.47 0.0052
Ectonucleotide pyrophosphatase/phosphodiesterase 1 ENPP1 0.47 0.0000
Inositol polyphosphate-4-phosphatase, type II, 105 kDa INPP4B 0.48 0.0001
Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase CILP 0.52 0.0001
Fructose-1,6-bisphosphatase 1 FBP1 0.58 0.0001
Protein tyrosine phosphatase, receptor type, T PTPRT 0.71 0.0001
Myotubularin-related protein 9 MTMR9 0.75 0.0064
Protein tyrosine phosphatase, receptor type, G PTPRG 0.75 0.0011
Calcium activated nucleotidase 1 CANT1 0.76 0.0931
Inositol polyphosphate-5-phosphatase J INPP5 J 0.80 0.0006
a FDR adjustment based on 262 features analyzed
444 Breast Cancer Res Treat (2016) 158:441–454
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subgroups (TNBC, mixed TNBC?Her2, and Her2-en-
riched) (Supplementary Table 1). One set of phosphatases,
which includes INPP4B, DUSP4, and CILP, is underex-
pressed in the TNBC subgroup compared to that in the
other 2 ER-negative subgroups, while another set, which
includes PPP3R1, PTPLA, and PTPRZ1, is overexpressed
in the TNBC subgroup compared to that in the other two
subgroups. A third set of phosphatases, which includes
CDC25B, NUDT1, and DLGAP5, is overexpressed in the
Her2-enriched subgroup compared to that in the other
subgroups (Supplementary Table 1).
We next examined the Breast Invasive Carcinoma
TCGA dataset (accessed through the cBioPortal for Cancer
Genomics on 01/15/2014) with the genetic alteration
Fig. 1 Phosphatases
differentially expressed in ER-
negative and ER-positive breast
cancers. a Supervised
hierarchical clustering of breast
cancers based on phosphatase
expression that distinguishes
ER-positive from ER-negative
breast tumors. Clinical
parameters (HER2, ER, Pam50)
are annotated for the samples
(x-axis), and gene signature is
annotated for the genes (y-axis).
b Hierarchical clustering
analysis of only ER-negative
breast tumors using the
phosphatases genes (as shown)
selected in a
Breast Cancer Res Treat (2016) 158:441–454 445
123
parameters to include both homozygous deletion and
heterozygous loss [20, 21]. We found that among the 5
phosphatases most underexpressed in ER-negative tumors,
DUSP4 was the only phosphatase with high-frequency
allele loss (Fig. 2a) and exhibited the highest degree of
homozygous deletion (Fig. 2b). DUSP4 is frequently
somatically altered (66.6 %) in breast cancers in the TCGA
dataset with high proportions of hetero (46.6 %)- and
homozygous deletion (5.3 %) (Fig. 2c). In addition to gene
loss, copy number gain (14 %), mRMA upregulation
(3.0 %), and amplification (0.83 %) also occur. We also
analyzed DUSP4 somatic alterations in both ER-negative
and TNBC populations (Supplementary Figure 1). For this
reason, we selected DUSP4 for further study. We next
conducted an examination of DUSP4 expression across 10
independent publically available breast cancer microarray
datasets (Supplementary Table 3) [22–31]. We selected
datasets with[100 patients which displayed differential
DUSP4 expression in ER-positive versus ER-negative
breast cancers (p\ 0.001). Differential expression of
DUSP4 was observed in all 10 datasets (two are shown in
Fig. 2d).
Fig. 2 Genomic alteration and
expression of phosphatases.
a Percent of all tumors with any
deletion among the top five
underexpressed genes in the
TCGA dataset. b Homozygous
deletion of selected
phosphatases in TCGA. c All
somatic alterations of DUSP4
gene represented by the cBio
Oncoprint. d Differential
expression of DUSP4 in two
breast cancer datasets
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Inducible expression of DUSP4 inhibits ER-negative
but not ER-positive breast cancer cell growth
in vitro
To determine the role of DUSP4 in regulating growth of
ER-negative breast cancer cells, we cloned the DUSP4 into
a tetracycline (Tet)-inducible vector (pTIPZ). Lentiviral
particles containing pTIPZ-DUSP4 or pTIPZ-vector were
infected and stable pools of ER-negative (SUM 159, MDA-
MB-231) and ER-positive (MCF-7) cell lines were gener-
ated by puromycin selection for doxycycline-inducible
DUSP4 expression. After 4 days of doxycycline induction,
DUSP4 expression was determined by Western blot using
anti-DUSP4 antibody. Our results show that after 4 days of
doxycycline treatment, DUSP4 expression was signifi-
cantly induced in all three cell lines (Fig. 3a).
We then determined the effect of DUSP4 on breast
cancer cell growth with and without doxycycline using the
trypan blue exclusion assay. Our results show that induced
DUSP4 expression strongly suppresses cell growth in
DUSP4-transfected ER-negative cell lines (SUM159: 89 %
repression; MDA-MB-231: 83 % repression), but not in
DUSP4-transfected MCF7 ER-positive breast cancer cells
(Fig. 3b–d, respectively). Conversely, no detectable change
in cell growth rate is associated with doxycycline treatment
in any of the vector-transfected cells. Collectively, these
results demonstrate induction of DUSP4 inhibits prolifer-
ation of ER-negative but not ER-positive breast cancer
cells.
Induction of DUSP4 inhibits anchorage-independent
growth of ER-negative but not ER-positive breast
cancer cells
We next investigated whether DUSP4 regulates anchorage-
independent growth of ER-negative and ER-positive breast
cancer cells using the doxycycline-inducible cell lines
described above. Our results show induced DUSP4
expression significantly suppresses anchorage-independent
growth of DUSP4-transfected ER-negative cells (SUM
159: 95 % suppression; MDA-MB-231: 85 % suppres-
sion), but not DUSP4-transfected MCF7 ER-positive cells
(Fig. 3e–g, respectively). Vector clones show no change in
anchorage-independent growth when treated with doxycy-
cline. These results further demonstrate that DUSP4
induction inhibits growth of ER-negative but not ER-pos-
itive breast cancer cells.
Induction of DUSP4 inhibits ER-negative breast
cancer growth in vivo
We next investigated whether DUSP4 expression inhibits
in vivo growth of TNBCs using nude and SCID mouse
models. After injected cell lines grew into tumors
approximately 50 mm3 in volume, mice were randomized
to receive either doxycycline-treated or nondoxycycline-
treated water. Growth rate of MDA-MB-231 vector clones
was not affected by doxycycline treatment (Fig. 4a).
However, strong suppression of tumor growth was asso-
ciated with doxycycline-induced DUSP4 expression in
MDA-MB-231 xenografts compared to nondoxycycline
treatment (Fig. 4c). Furthermore, while no difference in
growth rate (slope) was observed in MDA-MB-231-vector
control clones (Fig. 4b), there was a significant difference
in MDA-MB-231-DUSP4 clone growth rates depending on
the presence and absence of doxycycline (p = 0.03)
(Fig. 4d). Significant differences in tumor growth were also
observed in inducible SUM159–DUSP4 clones implanted
into the mammary fat pad of SCID mice in the presence or
absence of doxycycline, but not in SUM159-vector clones
(Fig. 4e, g). Similarly, while no difference was apparent in
the growth rate of SUM159-vector control clones, there
was a significant difference in the SUM 159-DUSP4 clone
growth rates in the presence and absence of doxycycline
(p = 0.0002) (Fig. 4f, h). As shown in Fig. 5a, b, Ki67
expression in MDA-MB-231 tumors (measured by
immunohistochemistry) was significantly reduced in the
DUSP4-transfected group treated with doxycycline
(p = 0.004). These results are consistent with our in vitro
studies and demonstrate that DUSP4 induction inhibits the
growth of ER-negative breast tumors in vivo.
Induction of DUSP4 inhibits invasion and causes
a cell cycle block
We next investigated the invasive potential of ER-negative
breast cancers before and after DUSP4 induction, and the
effect of DUSP4 overexpression on cell motility. Our data
show that DUSP4 induction slightly reduces migration of
ER-negative breast cancer cells (p = 0.002) (Fig. 5c, d)
and inhibits the invasiveness of MDA-MB-231 breast
cancer cells (Fig. 5e, f) (p = 0.00001). We then studied the
effect of DUSP4 on the cell cycle using flow cytometry
analysis and PI staining. Our results show that DUSP4
expression increases the proportion of cells in G0/G1
(p = 0.01) and reduces the G2/M population (Fig. 5g),
suggesting that a DUSP4-induced cell cycle blockade is
one of the mechanisms preventing growth of ER-negative
breast cancer cells.
Induced expression of DUSP4 inhibits the activation
of multiple signaling pathways
We next conducted RPPA protein microarray analyses of
172 proteins before and after DUSP4 overexpression to
determine the effects of DUSP4 on these proteins in ER-
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negative cells (Fig. 6a). DUSP4 overexpression signifi-
cantly affects a number of differentially expressed proteins
(Fig. 6a). The most commonly up-regulated and down-
regulated proteins are shown in Supplementary Table 2.
Induced DUSP4 expression significantly alters expression
of a number of signaling proteins, including several MAPK
family members. Our RPPA results indicate DUSP4
expression significantly reduces phosphorylation of ERK1/
2 at T202/204, p38 at T180/Y182, and JNK1 at T183/T185
(Fig. 6b). To confirm our RPPA results, we examined the
effect of DUSP4 expression on phospho-ERK1/2, pJNK1,
and phospho-p38 status by Western blot analysis. Our
results indicate DUSP4 down-regulates ERK1/2, JNK1,
and p38 signaling in both MDA-MB-231 and SUM 159
cells (Supplementary Figure 2). In addition, induced
DUSP4 overexpression also affected other signaling pro-
teins, resulting in significant inhibition of the phosphory-
lation of Rb (at S807/S811) and p65 (at S536), and
increases AMPK phosphorylation (Fig. 6c). Collectively,
these RPPA results suggest that DUSP4 induction signifi-
cant impacts growth regulatory kinases (ERK1/2, JNK1,
and p38) and downstream regulators of proliferation (p65
and Rb), which directly or indirectly reduce tumor growth
in ER-negative breast cancer cells.
Fig. 3 Induced expression of
DUSP4 inhibits ER-negative
but not ER-positive growth
in vitro. a Western blot analysis
of doxycycline-induced
expression of DUSP4 in
SUM159, MDA-MB-231, and
MCF7 breast cancer cells.
b–d Proliferation analysis of
breast cancer cell lines upon
expression of DUSP4.
e–g Anchorage-independent
colony formation assay of breast
cancer cell lines upon
expression of DUSP4
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Discussion
In this study, we identified phosphatases differentially
expressed in ER-negative compared to those in ER-positive
breast cancers. We found 31 phosphatases significantly
overexpressed and 11 phosphatases significantly underex-
pressed in ER-negative versus ER-positive breast cancers.
Included in the set of underexpressed phosphatases are
phosphatases regulating growth factor signaling pathways
(INPP4B, PTPRT, and DUSP4), as well as phosphatases
involved in gluconeogenesis (FPB1), nucleotide cleavage
(ENPP1), and metabolism (CANT1). Of these 11
underexpressed phosphatases, DUSP4 is the most com-
monly deleted phosphatase, deleted in approximately 50 %
of human breast cancers. Our results show that DUSP4
overexpression in TNBCs suppresses breast cancer cell
growth by suppression of MAPKs (ERK1/2, JNK1, and
p38), NFkB, and Rb signaling pathways, ultimately caus-
ing a cell cycle block.
DUSP4 is an early response gene synthesized after
growth factor stimulation [11, 32, 33] and has also been
mapped to a gene locus that is frequently lost in breast and
prostate cancer [34]. DUSP4 is localized in chromosome
8p, part or all of which is commonly lost in multiple
Fig. 4 Induction of DUSP4
expression inhibits the growth
of ER-negative breast cancer
cells in vivo. a Induced
expression of DUSP4 does not
inhibit in vivo xenograft growth
of MDA-MB-231 vector
clone ±Dox; b calculated slope
from MDA-MB-231 vector
clone xenograft. c MDA-MB-
231-DUSP4 clone ±Dox
growth curves; d calculated
slope from MDA-MB-231-
DUSP4 xenograft. e Induced
expression of DUSP4 does not
inhibit in vivo xenograft growth
of SUM 159-Vector
clone ±Dox growth curves;
f calculated slope from SUM
159-vector ±Dox, g SUM
159-DUSP4 clone ±Dox
growth curves; h calculated
slope from SUM 159-DUSP4
clone xenograft. t-test p values
are indicated
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cancers including breast cancer [35–38]. Armes et al. [34]
have shown loss of the DUSP4 gene and protein in early-
onset and high-grade breast cancer. DUSP4 loss or epige-
netic silencing has been described in lung cancer and
glioblastomas [15, 39, 40]. Re-expression of DUSP4 in
lung cancer cells with 8p loss and low endogenous DUSP4
reduces growth, while knockdown of DUSP4 in cell lines
with high DUSP4 expression enhances cell growth [15].
Our results are in agreement with these previously pub-
lished studies [34, 40, 41]; together, our results and those of
others suggest that DUSP4 is an important tumor sup-
pressor gene in breast cancer.
Balko et al. have demonstrated that DUSP4 mRNA
expression levels correlate inversely with MEK inhibitor
sensitivity, suggesting that DUSP4 expression is a bio-
marker for MEK inhibitor sensitivity in PTEN-positive
tumors [16, 42]. Our results also show that DUSP4 inhibits
ERK1/2 phosphorylation in TNBC cells, as well as p38 and
JNK1/2 phosphorylation. Since termination of MAPK
signaling is maintained by MAP phosphatases, lower
expression of DUSP phosphatases results in increased
MAPK activity [32, 43]. p38 has been shown to be
involved in cell proliferation and tumorigenesis [44], and
high levels of p38 in breast cancer patients correlates with
invasiveness and poor prognosis [45]. Previously, we have
shown that inhibition of the p38 kinase suppresses prolif-
eration of ER-negative breast cancer cells [19]. Our present
study suggests that inhibition of all three MAPKs by DUSP
Fig. 5 Increased DUSP4
expression causes reduced
proliferation, invasion, and a G1
cell cycle block.
a Representative Ki67 staining
of MDA-MB-231 xenograft
sections. b Quantitation of
Ki67; c representative pictures
of Boyden chamber assay for
migration for the cells before
and after DUSP4 induction.
d Relative migration in MDA-
MB-231; e representative
pictures of Boyden chamber
assay for invasion for the cells
before and after DUSP4
induction. f Relative invasion in
MDA-MB-231. g Cell cycle
changes after DUSP4 induction.
t-test p values are indicated
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expression has a stronger growth inhibitory effect than
inhibition of only ERK1/2 alone. Creighton et al. [46]
previously demonstrated that increased MAPK activity
causes loss of ERa expression and plays a role in the
generation of the ERa phenotype. Our results suggest
reduced expression of DUSP4 activates phosphorylation of
all three MAPKs. Therefore, regulation of DUSP4
expression may influence the generation of ERa-negative
breast cancer via MAPK activation. Expression of DUSP4
also inhibits NFkB and Rb signaling, in addition to MAPK
signaling, ultimately resulting in profound suppression of
growth.
In this study, we demonstrated that several other phos-
phatases (PPP1R3C, INPP4B, FBP1, PTPRT, MTMR9,
and CANT1) are underexpressed in ER-negative compared
to those in ER-positive breast cancers. The PPP1R3C gene
is hypermethylated in colorectal cancer (CRC) [47], and is
a candidate tumor suppressor gene in melanoma and is
inactivated through promoter methylation [48]. Gewinner
et al. have shown that INPP4B regulates the PI3 K pathway
and that its gene is located in a region frequently deleted in
both breast cancer cell lines and high-grade breast tumors
[49–51]. Deletion of INPP4B has been shown to increase
growth of breast cancer cells in vitro, and overexpression
of INPP4B reduces growth in vivo [49]. Another phos-
phatase underexpressed in ER-negative breast cancer is
FBP1. The FBP1 protein regulates glycolysis and epithe-
lial-to-mesenchymal transition in breast cells, and
Fig. 6 RPPA analysis identifies signaling pathways altered upon
induced expression of DUSP4. a RPPA analysis was performed on
SUM159 cells with and without induction of DUSP4 (–Dox = No
DUSP4 over expression and ?Dox = DUSP4 overexpression). Selec-
tive markedly altered proteins are indicated after DUSP4 expression.
The median expression values for each protein in cells treated with
Dox was subtracted from the protein expression value in cells treated
with vehicle to obtain a difference value for each protein studied.
Those proteins that showed the greatest change (increased or
decreased) are shown in Supplementary Table 2. b Changes in MAP
Kinase group: p-ERK1/2, p-p38, and p-JNK1/2. c Changes in the other
signaling pathways: p-Rb, p-p65 (S536), and p-AMPK (T172)
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overexpression of FBP1 reduces growth of breast cancer
cells [52]. The other phosphatases we identified as under-
expressed in ER-negative breast cancer (PTPRT, MTMR9,
CANT1, ENPP1, and CILP) may play important roles in
signal transduction and tumorigenesis in breast as well as
other cancers. Thus, this approach of examining the dif-
ferential expression of phosphatase genes in ER-positive
and ER-negative breast cancer has identified many
important phosphatases that regulate tumor growth and
tumorigenesis.
Through this genomic study of RNA from human
breast cancers, we identified specific phosphatases dif-
ferentially expressed in ER-negative breast cancers
compared to those in ER-positive breast cancers. For this
study, we focused on those phosphatases underexpressed
in ER-negative versus ER-positive breast cancer. Such
phosphatases may be important tumor suppressor genes
in ER-negative breast cancer. We also demonstrated that
DUSP4 controls the growth and invasiveness of ER-
negative breast cancer, and alters the phosphorylation of
several growth-promoting signaling proteins, including
three MAPKs (ERK, p38, and JNK) and NFjB. These
results suggest that targeting this pathway by targeting
the downstream genes ERK, p38, JNK, and NFjB, or by
reactivating DUSP4 (possibly by using demethylation
agents), provides a novel approach for the treatment of
ER-negative, and particularly triple-negative, breast
cancer.
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